Black Health

Sickle Cell · Topic guide

The Sickle Cell Adolescent-to-Adult Transition — Where Mortality Peaks

The transition from pediatric to adult sickle cell care between ages 18 and 30 is the single highest-mortality window in SCD — a gap driven by care fragmentation, insurance churn, and too few adult hematologists trained in SCD.

Body

The 18-30 mortality cliff

A 2014 analysis by Lanzkron et al. in the American Journal of Hematology and a subsequent CDC WONDER update showed that the age-specific SCD mortality curve in the U.S. rises sharply starting at age 18 — right when patients transition out of pediatric hematology and into adult care. Median age at SCD-related death in the U.S. remains in the early to mid-40s. Peer European populations with similar disease populations but more coordinated adult SCD programs reach median ages 55-60.

Why the cliff exists

  • Fewer adult hematologists know SCD. The ratio of trained pediatric SCD specialists to adult SCD specialists in the U.S. is roughly 5:1. Many adults end up in general internal medicine or the emergency department rather than in a comprehensive clinic.
  • Insurance churn. Many patients age out of parental plans at 26 and face new pre-authorization barriers for hydroxyurea, transfusion therapy, and other disease-modifying medications.
  • Care coordination stops. Pediatric clinics deliberately coordinate with schools, social work, and families. Most adult clinics assume the patient self-manages — a major shift.
  • ED pain undertreatment. Adult SCD patients face longer ED waits and higher suspicion of drug-seeking behavior than peer pediatric patients with identical crises.

What a transition program looks like

Leading transition programs — Duke Adult Sickle Cell Clinic, Johns Hopkins Sickle Cell Center for Adults, VCU Adult Sickle Cell, Emory/Grady, Boston Medical Center's Center of Excellence, Cincinnati Children's transition team — typically: (1) run a joint pediatric/adult clinic starting around age 16; (2) assign a transition coordinator who follows the patient through the handoff; (3) supply the patient with a personal medical summary, pain plan, and hematologist-signed ED letter; and (4) check in at 30, 60, and 90 days after the first adult-clinic visit to confirm continuity.

What to bring to your first adult-clinic visit

  • Your hemoglobin genotype (HbSS, HbSC, etc.)
  • Your most recent pediatric clinic note + TCD/echo result
  • A list of every hospitalization in the last 24 months
  • A list of all current medications including any PRN pain meds
  • Insurance card + photo ID
  • A list of the three or four things you want your adult hematologist to know about how you manage your disease — your triggers, what medications work for you in a crisis, and anything you want the ED to know.

For Black families

The 18–30 mortality gap is the sharpest edge of SCD inequity. A Black child diagnosed at birth in 2000, given penicillin prophylaxis, vaccinated, and followed by a pediatric SCD program, has every reason to expect to reach age 18 in good health — and then, in the gap between pediatric and adult hematology, preventable deaths spike. The 2014 Lanzkron et al. paper in the American Journal of Hematology quantified the shift: adult SCD patients in the U.S. die on average in their early to mid-40s, decades earlier than peer European populations with broadly similar disease. Transition clinics are the intervention.

More sickle cell topics

Comprehensive centers

What a Sickle Cell Comprehensive Care Center Actually Is — and How to Find One

Newborn screening

Sickle Cell Newborn Screening — Every State Screens, What Happens Next

Treatments

Sickle Cell Disease Treatments — Hydroxyurea to CRISPR Gene Therapy

ER pain crisis

Sickle Cell Pain Crisis in the ER — How to Advocate for Proper Treatment

Clinical trials

Active Sickle Cell Clinical Trials Recruiting Black Patients

References

  • NHLBI, "Evidence-Based Management of Sickle Cell Disease" (2014 expert panel report): nhlbi.nih.gov.
  • American Society of Hematology 2020 SCD Clinical Practice Guidelines: hematology.org.
  • CDC Sickle Cell Data Collection program: cdc.gov/ncbddd/hemoglobinopathies/scdc.
  • Sickle Cell Disease Association of America: sicklecelldisease.org.
  • Lanzkron S, Carroll CP, Haywood C, "Mortality rates and age at death from sickle cell disease: U.S. 1979–2005" (Am J Hematol 2013, expanded 2014).

Last updated: